Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 May 4:11:e45405.
doi: 10.2196/45405.

Exploring Digital Biomarkers of Illness Activity in Mood Episodes: Hypotheses Generating and Model Development Study

Affiliations
Observational Study

Exploring Digital Biomarkers of Illness Activity in Mood Episodes: Hypotheses Generating and Model Development Study

Gerard Anmella et al. JMIR Mhealth Uhealth. .

Abstract

Background: Depressive and manic episodes within bipolar disorder (BD) and major depressive disorder (MDD) involve altered mood, sleep, and activity, alongside physiological alterations wearables can capture.

Objective: Firstly, we explored whether physiological wearable data could predict (aim 1) the severity of an acute affective episode at the intra-individual level and (aim 2) the polarity of an acute affective episode and euthymia among different individuals. Secondarily, we explored which physiological data were related to prior predictions, generalization across patients, and associations between affective symptoms and physiological data.

Methods: We conducted a prospective exploratory observational study including patients with BD and MDD on acute affective episodes (manic, depressed, and mixed) whose physiological data were recorded using a research-grade wearable (Empatica E4) across 3 consecutive time points (acute, response, and remission of episode). Euthymic patients and healthy controls were recorded during a single session (approximately 48 h). Manic and depressive symptoms were assessed using standardized psychometric scales. Physiological wearable data included the following channels: acceleration (ACC), skin temperature, blood volume pulse, heart rate (HR), and electrodermal activity (EDA). Invalid physiological data were removed using a rule-based filter, and channels were time aligned at 1-second time units and segmented at window lengths of 32 seconds, as best-performing parameters. We developed deep learning predictive models, assessed the channels' individual contribution using permutation feature importance analysis, and computed physiological data to psychometric scales' items normalized mutual information (NMI). We present a novel, fully automated method for the preprocessing and analysis of physiological data from a research-grade wearable device, including a viable supervised learning pipeline for time-series analyses.

Results: Overall, 35 sessions (1512 hours) from 12 patients (manic, depressed, mixed, and euthymic) and 7 healthy controls (mean age 39.7, SD 12.6 years; 6/19, 32% female) were analyzed. The severity of mood episodes was predicted with moderate (62%-85%) accuracies (aim 1), and their polarity with moderate (70%) accuracy (aim 2). The most relevant features for the former tasks were ACC, EDA, and HR. There was a fair agreement in feature importance across classification tasks (Kendall W=0.383). Generalization of the former models on unseen patients was of overall low accuracy, except for the intra-individual models. ACC was associated with "increased motor activity" (NMI>0.55), "insomnia" (NMI=0.6), and "motor inhibition" (NMI=0.75). EDA was associated with "aggressive behavior" (NMI=1.0) and "psychic anxiety" (NMI=0.52).

Conclusions: Physiological data from wearables show potential to identify mood episodes and specific symptoms of mania and depression quantitatively, both in BD and MDD. Motor activity and stress-related physiological data (EDA and HR) stand out as potential digital biomarkers for predicting mania and depression, respectively. These findings represent a promising pathway toward personalized psychiatry, in which physiological wearable data could allow the early identification and intervention of mood episodes.

Keywords: Empatica E4; bipolar disorder; deep learning; depression; digital biomarker; machine learning; major depressive disorder; mania; physiological data; wearable.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: GA has received continuing medical education (CME)–related honoraria or consulting fees from Janssen-Cilag, Lundbeck, Lundbeck and Otsuka, and Angelini. IP has received CME-related honoraria, or consulting fees from ADAMED, Janssen-Cilag, and Lundbeck. IG has received grants and served as consultant, advisor or CME speaker for the following identities: Angelini, Casen Recordati, Ferrer, Janssen Cilag, and Lundbeck, Lundbeck-Otsuka, Luye, SEI Healthcare. AG-P has received CME-related honoraria, or consulting fees from Janssen-Cilag, Lundbeck, Casen Recordati and Angelini. MC has received grants and served as consultant, advisor or CME speaker for the following entities: Lundbeck, Esteve, Pfizer. NA has received CME-related financing from Janssen-Cilag, Lundbeck, Adamed, Pfizer, Angelini and Boston Scientific. MB has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of has received honoraria from talks and/or consultancy of Adamed, Angelini, Casen-Recordati, Exeltis, Ferrer, Janssen, Lundbeck, Neuraxpharm, Otsuka, Pfizer and Sanofi. NV has received financial support for CME activities and travel funds from the following entities: Angelini, Janssen-Cilag, Lundbeck, Otsuka. SM has received CME-related honoraria, or consulting fees from Janssen-Cilag, Lundbeck, Lundbeck/Otsuka, and Angelini. A Murru has received grants and served as consultant, advisor or CME speaker for the following entities: Angelini, Idorsia, Lundbeck, Pfizer, Takeda. LS has received CME-related honoraria, or consulting fees from Boehringer -Ingelheim, Janssen, Lundbeck/Otsuka, Sanofi-Aventis. AHY has received honoraria for lectures and advisory boards for all major pharmaceutical companies with drugs used in affective and related disorders. EV has received research support from or served as consultant, adviser or speaker for AB-Biotics, Abbott, Abbvie, Adamed, Angelini, Biogen, Celon, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, GH Research, Glaxo SmithKline, Janssen, Lundbeck, Organon, Otsuka, Rovi, Sage pharmaceuticals, Sanofi-Aventis, Shire, Sunovion, Takeda, and Viatris. DH-M has received CME-related honoraria and served as consultant for Abbott, Angelini, Ethypharm Digital Therapy and Janssen-Cilag. All authors report no financial or other relationship relevant to the subject of this article.

Figures

Figure 1
Figure 1
Study design and recordings. BD: bipolar disorder; HC: healthy controls; HDRS: Hamilton Depression Rating Scale; MDD: major depressive disorder; SCID: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders; T0: current acute Diagnostic and Statistical Manual of Mental Disorders–5 affective episodes; T1: symptoms’ response; T2: symptomatic remission; YMRS: Young Mania Rating Scale.
Figure 2
Figure 2
Permutation importance analysis. The height of the bars shows the change in accuracy at test time upon scrambling a channel through a random permutation of its values. A positive (negative) permutation importance value means that scrambling that channel results in a drop (increase) in accuracy relatively to the baseline where original (nonpermuted) values were used across all channels, that is, the channel’s permutation deteriorates (improves) the performance. A “0” permutation importance value indicates that a random permutation of the channel’s values does not affect accuracy in either direction. For instance, electrodermal activity (EDA) shows a positive change in accuracy of 40% for the intra-individual depressed BD severity prediction model; this means that removing this channel from the model would result in a decrease of prediction accuracy of 40%—from 62% to 22%—thus EDA is highly relevant for that model. Different colors correspond to the different tasks being investigated. ACC: acceleration; BD: bipolar disorder; BVP: blood volume pulse; HC: healthy controls; HR: heart rate; MDD: major depressive disorder; TEMP: temperature; T0: current acute Diagnostic and Statistical Manual of Mental Disorders–5 affective episodes; T1: symptoms’ response; T2: symptomatic remission.
Figure 3
Figure 3
Tile plots for the normalized mutual information analysis between physiological data and psychometric scales’ items: intra-individual level. For each scales’ item the mutual information (MI) with respect to each of the channels was measured and scaled to 0 to 1 dividing by the maximum MI value for that item. Values of zero indicate no associations, values of 1 indicate the maximum recorded MI across all channels for an individual item. ACC_X: x-axis acceleration; ACC_Y: y-axis acceleration; ACC_Z: z-axis acceleration; BD: bipolar disorder; BVP: blood volume pulse; EDA: electrodermal activity; HDRS: Hamilton Depression Rating Scale; HR: heart rate; MDD: major depressive disorder; TEMP: temperature; YMRS: Young Mania Rating Scale.
Figure 4
Figure 4
Tile plot for the normalized mutual information analysis between physiological data and psychometric scales’ items: between-individual level. For each scales’ item, the mutual information (MI) with respect to each of the channels was measured and scaled to 0 to 1 dividing by the maximum MI value for that item. Values of “0” indicate no associations; values of 1 indicate the maximum recorded MI across all channels for an individual item. ACC_X: x-axis acceleration; ACC_Y: y-axis acceleration; ACC_Z: z-axis acceleration; BVP: blood volume pulse; EDA: electrodermal activity; HC: healthy controls; HDRS: Hamilton Depression Rating Scale; HR: heart rate; TEMP: temperature; YMRS: Young Mania Rating Scale.
Figure 5
Figure 5
Severity versus Mood-Phase Classification Models: visual grounds for both intra- and inter-individual analyses. On the left, a severity classification model for a patient with depression (acute-response-remission phases). On the right, a mood-phase classification model (depression, mania, and euthymia). Note that on the left model, the same individual is compared at 3 different states (corresponding to a reduction in depressive psychopathology). Thus, individual-level characteristics (age, sex, and gait) should go through little to no variation across; should remain the same on the 3 longitudinal registers; and therefore, the shift in the covariate distribution should be relatively contained and not influence the classification of the model (capturing mood-relevant signals). In contrast, on the right, 3 different individuals at 3 different mood states are compared. In this case, the model would potentially distinguish between mood phases (mania vs depression), or cases from healthy controls, but may not be able to distinguish longitudinal changes in disease severity over the course of an index episode. In addition, in the latter model, subject-specific characteristics may be overlapped with mood-relevant signals, thus acting as confounders for the model. T0: current acute Diagnostic and Statistical Manual of Mental Disorders–5 affective episodes; T1: symptoms’ response; T2: symptomatic remission.

References

    1. COVID-19 Mental Disorders Collaborators Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021 Nov 06;398(10312):1700–12. doi: 10.1016/S0140-6736(21)02143-7. https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(21)02143-7 S0140-6736(21)02143-7 - DOI - PMC - PubMed
    1. Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, Gao K, Miskowiak KW, Grande I. Bipolar disorders. Nat Rev Dis Primers. 2018 Mar 08;4:18008. doi: 10.1038/nrdp.2018.8.nrdp20188 - DOI - PubMed
    1. Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med. 2020 Jul 02;383(1):58–66. doi: 10.1056/NEJMra1906193. - DOI - PubMed
    1. Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF. Major depressive disorder. Nat Rev Dis Primers. 2016 Sep 15;2:16065. doi: 10.1038/nrdp.2016.65.nrdp201665 - DOI - PubMed
    1. Jain SH, Powers BW, Hawkins JB, Brownstein JS. The digital phenotype. Nat Biotechnol. 2015 May;33(5):462–3. doi: 10.1038/nbt.3223.nbt.3223 - DOI - PubMed

Publication types